# Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.

> **NCT02882308** · PHASE2 · COMPLETED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 41 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Cisplatin
- **DRUG:** Olaparib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02882308
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-20
- **Primary completion:** 2019-12
- **Final completion:** 2020-01-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882308, "Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02882308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*